Click here
GLP-1 Receptor Agonists
A Pharmacist's Comprehensive Continuing Education Course — covering Type 2 Diabetes, Obesity, Cardiovascular Disease, Chronic Kidney Disease, Heart Failure, Peripheral Artery Disease, Obstructive Sleep Apnea, and the 2026 FDA approval of Foundayo (orforglipron)
Course Information
About This Activity
Author: Daniel Ballotti, PharmD — Staff Pharmacist, King Soopers Pharmacy #12, Pueblo, Colorado
Target Audience: Pharmacists, pharmacy interns, prescribers, and allied healthcare providers
Activity Type: Knowledge-based / Application-based
This continuing education activity is designed to provide pharmacists, pharmacy interns, prescribers, and allied healthcare professionals with a rigorous, evidence-based review of GLP-1 receptor agonist pharmacotherapy. The course encompasses the full clinical spectrum of this rapidly evolving drug class — from foundational mechanism of action to real-world dispensing challenges — with particular emphasis on the April 2026 FDA approval of Foundayo (orforglipron), the first oral non-peptide small-molecule GLP-1 receptor agonist.
Learners who complete this activity will be equipped to counsel patients, navigate formulary transitions, manage perioperative holds, and apply landmark cardiovascular and renal outcome trial data to individualized agent selection.
Course Scope
  • Type 2 Diabetes Mellitus
  • Obesity & Weight Management
  • Cardiovascular Disease
  • Chronic Kidney Disease
  • Heart Failure (HFpEF)
  • Peripheral Artery Disease
  • Obstructive Sleep Apnea
  • Switching, Microdosing & Compounding
  • Perioperative Management
  • Foundayo (orforglipron) — NEW 2026
Table of Contents
Course Navigation
1
Foundations
Learning Objectives · Background & Disease Context · Mechanism of Action
2
Pharmacology & Agents
Available GLP-1 RAs · Agent Comparison · Foundayo Spotlight
3
Indications & Evidence
T2DM · Obesity · CV Disease · CKD · HFpEF · PAD · OSA
4
Safety & Practice
Contraindications · Dosing · Monitoring · Adverse Effects · Interactions
5
Real-World & Special Topics
Counseling · Special Populations · Shortages · Compounding · Perioperative
6
Assessment
Clinical Vignettes · Key Takeaways · Self-Assessment Questions · References
Section 1
Learning Objectives
Upon completion of this continuing education activity, learners will be able to demonstrate mastery of the following competencies across knowledge-based and application-based domains. These objectives are designed to prepare pharmacists and allied healthcare providers for immediate clinical application in outpatient, ambulatory, and community pharmacy settings.
Mechanism of Action
Describe the mechanism of action of GLP-1 receptor agonists, the dual GLP-1/GIP receptor agonist tirzepatide, and the small-molecule, non-peptide GLP-1 partial agonist orforglipron — including their effects on glycemic control, body weight, cardiovascular outcomes, and renal protection.
Agent Comparison
Compare available GLP-1 receptor agonists (dulaglutide, exenatide, liraglutide, oral semaglutide, subcutaneous semaglutide, tirzepatide, and orforglipron [Foundayo]) with respect to efficacy, dosing, pharmacokinetics, route of administration, and FDA-approved indications.
Landmark Trial Data
Apply cardiovascular, renal, heart-failure, PAD, sleep-apnea, and obesity outcome trial data — SUSTAIN-6, LEADER, REWIND, PIONEER-6/SOUL, EXSCEL, SELECT, FLOW, STEP-HFpEF, SUMMIT, STRIDE, SURMOUNT-OSA, ATTAIN-1 — to agent selection in complex patients.
Patient Counseling
Counsel patients on safe use of GLP-1 RAs, including dosing, titration, adverse effects, perioperative considerations, the unique administration flexibility of Foundayo, and the risks of compounded products and microdosing.
Real-World Practice
Manage real-world pharmacy challenges — drug shortages, formulary switching, missed doses, perioperative holds, counterfeit product identification, and integration of Foundayo into an evolving formulary.
Section 2
Background and Disease Context
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were originally developed as glucose-lowering agents for type 2 diabetes mellitus (T2DM). Over the past decade, this class has rapidly evolved from a "diabetes drug" into a multi-system metabolic therapy platform — with established or emerging indications spanning obesity, atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), heart failure with preserved ejection fraction (HFpEF), peripheral artery disease (PAD), and most recently obstructive sleep apnea (OSA).
The commercial trajectory mirrors the clinical one: the global GLP-1 market is projected to reach approximately $200 billion by 2031, with more than 30 agents in development across oral, weekly, and dual/triple-receptor formulations. The April 2026 FDA approval of Foundayo (orforglipron) — the first oral, non-peptide, small-molecule GLP-1 receptor agonist — represents a meaningful expansion of access, lowering the practical and psychological barriers (injections, cold-chain storage, fasting requirements) that have limited uptake in populations who are otherwise excellent candidates for this therapy.

CLINICAL PEARL: GLP-1 receptor agonists are no longer simply glucose-lowering drugs. They are cardiometabolic disease modifiers with proven benefit across diabetes, obesity, cardiovascular disease, kidney disease, heart failure, and obstructive sleep apnea — and, with the 2026 approval of Foundayo, available in a true oral non-peptide form for the first time.
The GLP-1 Era: A Timeline of Expanding Indications
The clinical expansion of the GLP-1 class has been remarkably rapid, progressing from a single indication to a multi-organ disease-modifying platform within two decades.
1
2005
Exenatide IR (Byetta) — first GLP-1 RA approved for T2DM
2
2010
Liraglutide (Victoza) approved; daily SC formulation
3
2016
LEADER trial: liraglutide cuts CV death in T2DM + CVD
4
2021
Tirzepatide Phase 3 (SURPASS); semaglutide obesity trials (STEP)
5
2023–24
SELECT trial: GLP-1 reduces CV events in obesity without T2DM; FLOW trial: semaglutide cuts CKD progression
6
2024–26
OSA approval (tirzepatide); Foundayo (orforglipron) — first oral non-peptide GLP-1 RA
Section 3
Mechanism of Action
Understanding the mechanism of action matters clinically because it explains much more than how GLP-1 receptor agonists lower glucose. Although these drugs are often described as “diabetes drugs” or “weight loss drugs,” that framing undersells their biology. Their receptor-level effects help explain why they influence appetite, fasting glucose, postprandial glucose, cardiovascular risk, kidney outcomes, and even drug tolerability at the same time. This is why the mechanism is not just academic background: it is the foundation for predicting adverse effects, anticipating drug interactions, explaining benefits to patients, and making rational agent-selection decisions. In practice, mechanism knowledge is what lets a pharmacist or clinician move from memorizing facts to understanding why this class works so broadly across organ systems.
Native glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted by intestinal L-cells in response to nutrient ingestion. It stimulates glucose-dependent insulin release, suppresses glucagon secretion, slows gastric emptying, and promotes satiety through central nervous system pathways. Endogenous GLP-1 is rapidly degraded by dipeptidyl peptidase-4 (DPP-4) and has a half-life of only 1–2 minutes, making it unsuitable for therapeutic use in its native form.
GLP-1 receptor agonists are engineered to resist DPP-4 degradation while retaining high-affinity receptor activity. The downstream pharmacologic effects extend well beyond glucose lowering, encompassing appetite regulation, cardiometabolic protection, and direct organ-level effects on the kidney, myocardium, and vasculature.
Core Pharmacologic Effects
  • Glucose-dependent enhancement of pancreatic β-cell insulin secretion
  • Suppression of inappropriate glucagon from pancreatic α-cells
  • Delayed gastric emptying, blunting postprandial glucose excursions
  • Central appetite suppression and increased satiety signaling
  • Modest blood pressure reduction and lipid parameter improvement
  • Direct effects on cardiomyocytes, vascular endothelium, and renal tissue — contributing to organ protection independent of glycemic and weight effects
Foundational Concepts
What Is an Incretin Hormone?
An incretin is a gut-derived hormone released in response to nutrient ingestion that amplifies insulin secretion in a glucose-dependent manner. This is the physiologic logic behind the “incretin effect,” which describes the observation that oral glucose produces a much larger insulin response than the same amount of glucose given intravenously. In healthy individuals, this difference accounts for approximately 50–70% of postprandial insulin secretion. The two main incretins are GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide); both are rapidly degraded by DPP-4. In type 2 diabetes, the incretin effect is impaired because GLP-1 secretion is reduced and GLP-1 receptor sensitivity is diminished. GLP-1 receptor agonists bypass that impairment by delivering supraphysiologic receptor stimulation directly.

Clinical implication: GLP-1 RAs do not merely “help the pancreas work harder.” They restore and amplify a natural post-meal signaling pathway that is deficient in diabetes.
What Is DPP-4 and Why Does It Matter?
DPP-4 (dipeptidyl peptidase-4) is a ubiquitous serine protease found in the gut, kidney, liver, and plasma. It cleaves the N-terminal dipeptide from GLP-1, inactivating it within 1–2 minutes. This is why native GLP-1 cannot be used as a drug: it is destroyed almost immediately. GLP-1 receptor agonists are structurally modified to resist DPP-4 cleavage, which gives them half-lives ranging from hours, as with exenatide IR, to days, as with semaglutide and tirzepatide.
DPP-4 inhibitors such as sitagliptin and linagliptin work differently. They block the enzyme to preserve endogenous GLP-1 longer, whereas GLP-1 receptor agonists bypass the enzyme entirely by providing exogenous receptor stimulation. Because these strategies act on the same pathway, combining them is generally redundant and does not provide meaningful additive benefit.
Glucose-Dependent Mechanism — Why It Matters for Safety
GLP-1 receptor activation is glucose dependent. On pancreatic beta cells, GLP-1 receptors are coupled to adenylyl cyclase. When GLP-1 binds, intracellular cAMP rises and potentiates glucose-stimulated insulin secretion — but only when glucose is already elevated. At normal or low glucose levels, the signal is not sufficient to drive meaningful insulin release. This is a major safety feature: when used as monotherapy, GLP-1 receptor agonists have a very low intrinsic risk of hypoglycemia. By contrast, sulfonylureas stimulate insulin release regardless of glucose level.
GLP-1 also suppresses glucagon from pancreatic alpha cells in a glucose-dependent manner. Inappropriately elevated glucagon is a major contributor to fasting hyperglycemia in type 2 diabetes, so lowering glucagon reduces hepatic glucose output and improves fasting glucose control.
Detailed Explanation — The Five Pharmacologic Effects
Effect 1: Pancreatic Beta-Cell Insulin Stimulation
GLP-1 binds to GLP-1 receptors on beta cells and increases cAMP, which potentiates glucose-stimulated insulin secretion. The clinical result is meaningful A1c reduction, typically 1–2% with semaglutide and up to 2.4% with tirzepatide, without the hypoglycemia risk seen with insulin or sulfonylureas. Over time, some evidence suggests GLP-1 receptor agonists may help preserve beta-cell mass and function by reducing glucotoxicity and lipotoxicity, although this remains an active area of research.
Effect 2: Glucagon Suppression
GLP-1 receptors on alpha cells suppress glucagon release when glucose is elevated, which reduces hepatic glucose output through both gluconeogenesis and glycogenolysis. This effect is a major contributor to fasting glucose reduction and is often underappreciated. Many patients with type 2 diabetes have fasting hyperglycemia driven in part by excess glucagon, not just insufficient insulin. Because this mechanism is also glucose-dependent, it does not create hypoglycemia at normal glucose levels.
Effect 3: Delayed Gastric Emptying
GLP-1 receptors in the enteric nervous system and on vagal afferents slow gastric motility, reducing the rate at which nutrients enter the small intestine. Clinically, this blunts postprandial glucose excursions by slowing carbohydrate absorption and also contributes to satiety by prolonging gastric distension. It is the primary driver of GI adverse effects such as nausea, vomiting, and early satiety, and it explains important drug interactions related to delayed absorption of co-administered oral medications.
The gastric emptying effect is most pronounced early in therapy and during dose escalation, and it tends to attenuate somewhat with continued use. That is one reason GI side effects often improve over time. However, interaction risk with narrow-therapeutic-index drugs still matters and should not be ignored.
Effect 4: Central Appetite Suppression and Satiety
GLP-1 receptors are expressed in the hypothalamus, including the arcuate and paraventricular nuclei, as well as in the brainstem, including the nucleus tractus solitarius. GLP-1 receptor agonists can cross the blood-brain barrier or act at circumventricular organs to activate these satiety centers. They reduce hunger signaling, decrease the reward value of food, and increase the sensation of fullness. This central effect is the primary driver of weight loss with this class; it is not simply “eating less because you feel sick.” It reflects a genuine neurobiological reduction in appetite and food-seeking behavior, which is important for patient counseling.
Tirzepatide also activates the GIP receptor, which is expressed in the brain and adipose tissue. This dual GLP-1/GIP agonism appears to produce additive or synergistic appetite suppression and weight loss beyond GLP-1 alone, helping explain its superior efficacy for both A1c lowering and weight reduction.
Effect 5: Direct Cardiorenal and Vascular Effects
GLP-1 receptors are expressed on cardiomyocytes, vascular endothelial cells, smooth muscle cells, and renal tubular cells. Direct receptor activation produces anti-inflammatory, anti-atherosclerotic, and natriuretic effects that are not fully explained by glucose lowering or weight loss alone. In the cardiovascular system, GLP-1 signaling reduces oxidative stress, improves endothelial function, modestly lowers blood pressure, and may provide direct anti-ischemic effects on the myocardium. These mechanisms help explain the cardiovascular outcome trial results seen in LEADER, SUSTAIN-6, and SELECT, including MACE reduction even in patients without diabetes.
In the kidney, GLP-1 receptor activation in the proximal tubule and glomerulus contributes to natriuresis, reduced glomerular hyperfiltration, and anti-inflammatory effects. These mechanisms support the nephroprotective findings in FLOW and align with KDIGO and ADA recommendations for GLP-1 receptor agonists in chronic kidney disease. Importantly, the LEADER trial suggested cardiovascular benefit even with only modest A1c improvement, reinforcing that these effects extend beyond metabolic control alone.
Mechanism, Process, or Logic — How the Effects Connect
The five pharmacologic effects are not isolated actions; they operate as one integrated physiologic system. The pancreatic effects address the core hormonal defect in type 2 diabetes by increasing insulin when needed and lowering inappropriate glucagon. The delayed gastric emptying effect smooths postprandial glucose and contributes to satiety. The central appetite effect drives sustained weight loss, which secondarily improves insulin resistance, blood pressure, and lipid parameters. The direct cardiorenal effects add organ protection on top of the metabolic benefits. Together, these mechanisms explain why GLP-1 receptor agonists can simultaneously improve A1c, reduce weight, lower blood pressure, protect the kidneys, and reduce cardiovascular events. This happens not because the drugs are doing five unrelated things, but because one receptor system is expressed throughout the body in tissues that matter clinically.
1
1
Step 1
Pancreatic Effects → Insulin ↑, Glucagon ↓
2
2
Step 2
Gastric Emptying ↓ → Postprandial glucose smoothed
3
3
Step 3
Central Appetite ↓ → Sustained weight loss
4
4
Step 4
Weight loss → Insulin resistance ↓, BP ↓, Lipids ↓
5
5
Step 5
Direct Cardiorenal Effects → Organ protection
Practical Significance
Mechanism knowledge translates directly into safer, more effective practice. Nausea and vomiting are expected consequences of delayed gastric emptying and central appetite suppression, so patients can be counseled that these effects are dose-dependent and often transient rather than signs of harm. The same delayed gastric emptying also explains why narrow-therapeutic-index oral drugs need closer monitoring, regardless of which GLP-1 receptor agonist is used. When patients understand that the medication is acting on the brain, gut, pancreas, heart, and kidneys simultaneously, they are often more willing to persist through early gastrointestinal effects.
Mechanistic differences also help guide agent selection. Tirzepatide’s added GIP agonism explains its stronger weight loss and A1c efficacy. Semaglutide’s cardiovascular outcome data help explain why it is often preferred in patients with established ASCVD. In other words, knowing the mechanism helps clinicians match the drug to the patient rather than choosing by brand familiarity alone.
Important Nuances
  • The glucose-dependent mechanism is a safety feature, not a limitation: it makes GLP-1 receptor agonists among the safest glucose-lowering agents with respect to hypoglycemia when used alone.
  • The gastric emptying effect attenuates over time, but the appetite-suppressing and cardiorenal effects are sustained, which helps explain why long-term efficacy persists even as gastrointestinal side effects improve.
  • GLP-1 receptor agonists do not cure type 2 diabetes or obesity. Weight regain and glycemic deterioration commonly occur when therapy is stopped because the underlying disease remains present.
  • The mechanism of orforglipron (Foundayo) is identical to injectable GLP-1 receptor agonists at the receptor level. It is a non-peptide small molecule that binds the same GLP-1 receptor; the difference is structural and pharmacokinetic, not pharmacodynamic.

Bottom line: The class works because one receptor system is strategically positioned across multiple organs. That is why the clinical effects are broad, coordinated, and biologically coherent.
GLP-1 receptor agonists work because GLP-1 receptors are everywhere that matters — the pancreas, gut, brain, heart, blood vessels, and kidneys. Understanding this receptor distribution is not just pharmacology trivia; it is the clinical logic that explains every major benefit, every major adverse effect, and every major drug interaction in this class.
Mechanism Subtypes: Beyond Standard GLP-1 Agonism
Tirzepatide — Dual GLP-1 / GIP
A single molecule activating both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. Dual agonism amplifies insulin secretion, enhances lipid metabolism, and produces greater weight loss than selective GLP-1 agonism alone. This explains tirzepatide's position as the most potent agent in the class for both A1c reduction and weight loss.
Orforglipron — Non-Peptide Partial Agonist
Structurally and pharmacologically distinct from all peptide-based agents. Its small molecular size and resistance to GI degradation enable reliable oral absorption without permeation enhancer technology. Orforglipron is a partial GLP-1 receptor agonist — a design choice intended to retain efficacy while potentially modulating adverse-effect intensity at higher doses.
Renal Protection — Metabolic Pathway
Unlike SGLT2 inhibitors (hemodynamic mechanism), GLP-1 RAs protect kidneys through metabolic and anti-inflammatory pathways: reduction in intraglomerular pressure, reduction in inflammation and oxidative stress, reduction in albuminuria, and reduction in metabolic burden on the renal tubules. Complementary — not redundant — to SGLT2 inhibition.
OSA — Airway Adiposity Reduction
Tirzepatide is not a direct airway drug. Reductions in total adiposity, and critically in upper-airway adiposity, translate into reduced airway collapse during sleep, with corresponding reductions in the apnea-hypopnea index (AHI). This represents the first time in modern medicine that a metabolic drug has been approved to treat a respiratory condition.

HIGH-YIELD: GLP-1 RAs achieve cardiovascular, renal, and OSA benefits through both weight-loss-dependent and weight-loss-independent mechanisms. The independent mechanisms — anti-inflammatory, vascular, and direct receptor effects on cardiomyocytes and renal tissue — explain why outcome benefits in trials are not fully accounted for by weight reduction alone.
Section 4
Pharmacology and Available Agents
Eight GLP-1 RA molecules are now commercially available in the United States across oral and subcutaneous routes, with daily, twice-daily, and weekly dosing schedules. Tirzepatide, marketed as Mounjaro for T2DM and Zepbound for chronic weight management and OSA, remains the only currently available dual GLP-1/GIP receptor agonist. Orforglipron, approved by the FDA on April 1, 2026 and marketed as Foundayo, is the first oral non-peptide small-molecule GLP-1 receptor agonist and is approved exclusively for chronic weight management.

CLINICAL PEARL: Tirzepatide's weekly subcutaneous administration combined with the longest mean half-life among weekly agents (~5–6 days) supports flexible scheduling and forgiveness for occasional missed doses. Foundayo's once-daily oral administration without food or water restrictions removes the most common adherence barriers cited by GLP-1-naive patients. Conversely, exenatide IR's 2.4-hour half-life requires twice-daily administration and limits its role in modern practice.
4.1 Available GLP-1 / GIP-GLP-1 Receptor Agonists — Comparison
New 2026 Approval
4.2 Spotlight: Foundayo (orforglipron)
The First Oral Non-Peptide GLP-1 Receptor Agonist
Foundayo (pronounced fown-DAY-oh) received FDA approval on April 1, 2026 — the fastest approval of a new molecular entity since 2002 (50 days from submission), and the first NME granted under the Commissioner's National Priority Voucher (CNPV) pilot program. Eli Lilly licensed orforglipron from Chugai Pharmaceutical in 2018.
Small-Molecule Partial Agonist
non-peptide, chemically synthesized
Once Daily, Any Time
with or without food, no fasting required
~29–49 hr Half-Life
supports stable once-daily plasma levels
No Cold Chain
room temperature storage, travel-friendly
Peptide GLP-1 RAs — The Old Paradigm
  • Amino acid chains; fragile in GI tract
  • Require injection OR complex oral delivery (SNAC)
  • Rybelsus: empty stomach, ≤4 oz water, 30-min fast, ~1% bioavailability
  • Injection anxiety, cold-chain storage, technique errors
Foundayo — The New Paradigm
  • Small molecule; GI-stable, absorbed without special technology
  • Oral tablet, any time, with or without food
  • No SNAC, no fasting, no injection
  • Room-temperature storage; six precise dose strengths

Foundayo is a partial agonist at the GLP-1 receptor — but partial agonism ≠ partial efficacy. ATTAIN-1 demonstrated clinically meaningful weight loss, confirming sufficient receptor activation for therapeutic benefit.
Foundayo is approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, such as hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease. It is not yet approved for type 2 diabetes glycemic control because the pivotal diabetes trials (ATTAIN-2 and ATTAIN-3) were still ongoing when the obesity approval was granted; future label expansion is anticipated but not confirmed. In practical use, if a patient with type 2 diabetes is prescribed Foundayo, it is for weight management rather than as a diabetes medication, and glycemia is typically being managed with other agents. Foundayo should not be substituted for Rybelsus or other GLP-1 receptor agonists used specifically for type 2 diabetes glycemic control, because the indications differ and such substitution would be off-label. Glycemic improvement may still occur as a secondary effect — ATTAIN-1 showed improvements in A1c and fasting glucose as secondary endpoints — but that does not constitute a labeled indication and should not drive prescribing or substitution decisions.

01
First Fill
Confirm weight management indication; verify 0.8 mg start dose; provide titration schedule; emphasize any-time dosing vs. Rybelsus
02
GI Counseling
Nausea, vomiting, diarrhea expected during titration; smaller meals, hydration, gradual escalation
03
Safety Review
Boxed warning: thyroid C-cell tumor risk (shared by all GLP-1 RAs except exenatide IR); contraindicated in MTC/MEN2 history
04
Ongoing Monitoring
Miss >2 days → restart from lowest dose; check for dual GLP-1 RA use; monitor for alopecia and fatigue (postmarketing requirements)
Foundayo ≠ Rybelsus
different molecule, different mechanism, different administration, different indication; never interchangeable
Partial agonism ≠ partial efficacy
ATTAIN-1 confirms therapeutic benefit
Glycemic improvement may still occur
secondary endpoints showed A1c/fasting glucose improvement, but not a labeled indication
No CV outcome data yet
cardiovascular outcome trial ongoing; no MACE-reduction label
50-day approval ≠ weak evidence
ATTAIN-1 was a rigorous 72-week Phase 3 trial
Foundayo is not just a more convenient GLP-1 RA — it is a different kind of molecule. As the first non-peptide small-molecule GLP-1 receptor agonist, it removes the structural, logistical, and adherence barriers that have limited GLP-1 therapy for years. The pharmacist who understands what makes Foundayo distinct — and what it does not yet do — is equipped to counsel patients accurately, prevent dangerous substitutions, and help this new agent reach the patients who will benefit most.
Foundayo — ATTAIN-1 Pivotal Trial Results
ATTAIN-1 was a 72-week, randomized, double-blind, placebo-controlled Phase 3 trial in adults with obesity or overweight with ≥1 weight-related comorbidity. The 36 mg orforglipron capsule used in trials is dose-equivalent to the 17.2 mg FDA-approved tablet strength.
ATTAIN-2 (adults with T2DM) demonstrated weight reductions of 5.1% (5.5 mg), 7.0% (9 mg), and 9.6% (17.2 mg) versus 2.5% with placebo — supporting safety and weight outcomes in diabetes but not securing a separate T2DM glycemic indication at this time.
Foundayo — Dosing and Titration
Each dose step requires a minimum of 30 days before advancing. The maintenance dose is selected based on individual treatment response and tolerability. Do not exceed one tablet per day. Do not co-administer with any other GLP-1 receptor agonist — this is an explicit labeled warning for Foundayo.

WARNING: Do NOT co-administer Foundayo with any other GLP-1 receptor agonist, including injectable agents, even at "microdosed" levels. This is now a labeled contraindication for orforglipron.
Foundayo — Safety, Warnings, and Access
Warnings and Precautions

BOXED WARNING: Risk of thyroid C-cell tumors. Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2). Same class warning as injectable peptide GLP-1 RAs.
  • Pancreatitis — discontinue if suspected
  • Severe gastrointestinal reactions
  • Acute kidney injury from GI-related volume depletion
  • Hypoglycemia when combined with insulin or sulfonylureas
  • Hypersensitivity reactions
  • Diabetic retinopathy progression in T2DM patients
  • Acute gallbladder disease (cholelithiasis, cholecystitis)
  • Pulmonary aspiration during anesthesia (delayed gastric emptying)
  • Hair loss — notable and underreported; counsel proactively
Access and Pricing (2026)
  • Initial distribution: LillyDirect direct-to-consumer; broader retail rolling out April–May 2026
  • Self-pay (starter 0.8 mg): ~$149/month
  • Self-pay (higher doses): ~$349/month
  • Commercial insurance + savings card: as little as $25/month
  • Medicare Part D: as little as $50/month (effective July 1, 2026)
  • No cold-chain storage required
  • No sharps disposal required
  • No fasting requirement

Postmarketing studies required by FDA: cardiovascular safety (stroke, MI) and hepatic safety (drug-induced liver injury). Pharmacists should anticipate evolving safety language as these data mature.
HIGH-YIELD DISTINCTION
Foundayo ≠ Rybelsus
Rybelsus (oral semaglutide) is a peptide that survives the GI tract only through the SNAC permeation enhancer, demanding empty-stomach dosing with ≤4 oz water and a 30-minute fast. Foundayo is a non-peptide small molecule with reliable absorption regardless of food intake, timing, or water volume. This is the single most important counseling distinction separating the two oral GLP-1 products on the market. Memorize it.
Rybelsus (Oral Semaglutide)
  • Peptide-based; requires SNAC enhancer
  • Empty stomach only
  • ≤4 oz water only
  • 30-minute fast post-dose
  • FDA-approved for T2DM
Foundayo (Orforglipron)
  • Non-peptide small molecule; no enhancer needed
  • Any time of day
  • With or without food
  • Any volume of water
  • FDA-approved for chronic weight management ONLY
Section 5.1
Glycemic Control in Type 2 Diabetes
The 2025 American Diabetes Association (ADA) Standards of Care position GLP-1 RAs as preferred agents — independent of metformin and independent of baseline A1c — in patients with established ASCVD, high cardiovascular risk, CKD, heart failure, or who would benefit from weight management. The default first-line regimen for patients without these compelling indications remains metformin plus comprehensive lifestyle intervention.
Across the class, GLP-1 RAs lower A1c by approximately 0.5%–2.5%, with tirzepatide demonstrating the greatest reductions observed in the class and exenatide demonstrating the most modest effects. Understanding this potency hierarchy is essential for agent selection when glycemic control is the primary driver of therapy decisions.

CLINICAL PEARL: If maximum A1c reduction is required, choose tirzepatide. Foundayo is NOT labeled for T2DM despite encouraging ATTAIN-2 data — off-label use for glycemic control is not currently supported.
Section 5.2
Weight Management — Efficacy Across the Class
GLP-1 RAs produce clinically meaningful, sustained weight reduction that surpasses older anti-obesity agents (phentermine, naltrexone-bupropion, orlistat) and is superior to most non-GLP-1 prescription options. The magnitude of weight loss varies substantially between agents and between the diabetes and non-diabetes populations — a distinction with real clinical relevance for agent selection and patient counseling.
Weight Loss in T2DM Population
Weight Loss in Non-Diabetes (Obesity) Population

CLINICAL PEARL: Real-world weight loss is generally less than trial outcomes due to imperfect adherence and GI-related early discontinuation. Counsel patients on Foundayo to expect ~10%–12% weight reduction at the highest tolerated dose — meaningful, but not the 15%–20% achievable with tirzepatide.
Section 5.3
Cardiovascular Disease — The SELECT Paradigm Shift
The 2025 ADA Standards of Care recommend a GLP-1 RA with proven cardiovascular benefit as first-line in adults with T2DM and either established ASCVD or high cardiovascular risk (age ≥55 with ≥2 of: hypertension, dyslipidemia, smoking, obesity). The SELECT trial in 2023 fundamentally expanded this principle: GLP-1 RAs are now cardiovascular drugs, not just diabetes medications. Subcutaneous semaglutide (Wegovy) is now FDA-approved for cardiovascular risk reduction in adults with overweight or obesity and established cardiovascular disease — even in the absence of diabetes.
The following agents carry FDA approval for major adverse cardiovascular event (MACE) reduction: dulaglutide (REWIND), liraglutide (LEADER), and subcutaneous semaglutide (SUSTAIN-6 / SELECT). Exenatide demonstrated noninferiority in EXSCEL but not superiority, and therefore does not carry a MACE indication. Tirzepatide and orforglipron do not currently carry formal MACE indications; FDA-required postmarketing studies are ongoing for Foundayo.
Landmark Cardiovascular Outcome Trials (CVOTs)

HIGH-YIELD: The SELECT trial redefined the class. GLP-1 RAs are cardiovascular drugs. Foundayo's CV story remains to be written — weight-loss-mediated reductions in waist circumference, non-HDL, triglycerides, and SBP in ATTAIN-1 are encouraging but do not constitute a cardiovascular outcome trial.
Section 5.4
Chronic Kidney Disease
The intersection of T2DM and CKD has become one of the most critical practice domains for GLP-1 RAs. The 2024 KDIGO Clinical Practice Guideline for Diabetes Management in CKD and the 2025 ADA Standards of Care now position GLP-1 RAs as a compelling-indication tier therapy — alongside ASCVD — in patients with T2DM and either eGFR <60 mL/min/1.73 m² or albuminuria.
In 2025, subcutaneous semaglutide (Ozempic) became the first GLP-1 RA to receive a formal FDA indication for kidney protection — specifically, reduction of the risk of kidney disease progression, kidney failure, and cardiovascular death in adults with T2DM and CKD — based on the landmark FLOW trial. This represents a major milestone: injectable semaglutide now carries FDA approvals across T2DM, obesity, cardiovascular risk reduction, and CKD. Foundayo does not currently carry a kidney indication; ATTAIN trials were not powered for kidney outcomes.
GLP-1 RA vs SGLT2 Inhibitor — Clinical Decision Framework
Both drug classes offer cardiorenal protection, but through distinct mechanisms. The real-world decision is rarely either/or — combination therapy is now supported by both ADA and KDIGO guidelines when tolerability, cost, and access permit.

CLINICAL PEARL — REAL-WORLD STRATEGY: When CKD is dominant, consider an SGLT2 inhibitor first. When weight or A1c is dominant, consider a GLP-1 RA first. When both apply — the typical real-world patient — use both if tolerability, cost, and access permit. Combination therapy is supported by both ADA and KDIGO guidance. Injectable semaglutide ≠ oral semaglutide for renal endpoints: SOUL was neutral. Foundayo has no CKD outcome data and does not change this hierarchy.
Section 5.5
Heart Failure — HFpEF Focus
Heart failure with preserved ejection fraction has historically been a difficult-to-treat phenotype, with limited disease-modifying options outside of SGLT2 inhibitors. Two pivotal trials have now brought GLP-1 / GIP-GLP-1 RAs into the HFpEF conversation, reshaping how pharmacists should counsel patients with this challenging diagnosis.
STEP-HFpEF (Semaglutide)
Improved Kansas City Cardiomyopathy Questionnaire scores, 6-minute walk distance, and body weight in both T2DM and non-DM cohorts. However, no reduction in hard outcomes (heart failure hospitalization or cardiovascular death) was observed. The benefit was symptomatic — clinically meaningful, but not outcome-modifying at this time.
SUMMIT (Tirzepatide) — The Stronger Signal
Hazard ratio 0.62 for the composite of cardiovascular death or worsening heart failure event, with an NNT of approximately 19 over ~2 years. Benefit was primarily driven by reduction in heart failure exacerbations. This result positions tirzepatide as the preferred agent in HFpEF patients who also have obesity — pending formal guideline integration.
Foundayo in HFpEF
No HF outcome data are available for orforglipron at this time. Pharmacists should not position Foundayo as a heart failure therapy and should not substitute it for tirzepatide or semaglutide in patients where HFpEF management is a driver of agent selection.
Section 5.6 & 5.7
Peripheral Artery Disease and Obstructive Sleep Apnea
Peripheral Artery Disease — STRIDE Trial
The STRIDE trial of semaglutide in patients with T2DM and symptomatic PAD demonstrated a clinically meaningful improvement in maximum walking distance: +87 m versus +41 m with placebo (~13% relative improvement). This functional gain is an underrated real-world benefit, particularly in patients whose mobility limits independence and quality of life. Foundayo has no PAD outcome data; semaglutide remains the agent of choice when PAD functional benefit is a therapeutic priority.
Obstructive Sleep Apnea — SURMOUNT-OSA
In December 2024, tirzepatide (Zepbound) became the first and currently only pharmacologic agent FDA-approved for moderate-to-severe OSA in adults with obesity — a historic paradigm shift. Approximately 50% of treated patients achieved remission or mild disease at 1 year.

HIGH-YIELD: Tirzepatide is the only true OSA game-changer in this class. Foundayo has no OSA outcome data and should not be substituted for tirzepatide in patients with this indication. CPAP works faster and is preferred for acute symptom relief; tirzepatide offers long-term disease modification through weight loss.
Section 6
Contraindications and Precautions

BOXED WARNING — ALL GLP-1 / GIP-GLP-1 RAs (Including Foundayo, except exenatide IR): Risk of thyroid C-cell tumors. GLP-1 RAs caused thyroid C-cell tumors at clinically relevant exposures in rodents; human relevance has not been determined. These agents are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with multiple endocrine neoplasia syndrome type 2 (MEN-2). Counsel all patients to report new neck masses, hoarseness, dysphagia, or persistent dyspnea.
Hypersensitivity
Contraindicated with prior hypersensitivity to the agent or any formulation component
Pancreatitis History
Use with caution; discontinue immediately if pancreatitis is suspected
Severe Gastroparesis
Relative contraindication due to delayed gastric emptying — may worsen symptoms
Pregnancy / Lactation
Contraindicated; discontinue ≥2 months before planned conception for weekly agents
Dual GLP-1 RA Use
Explicitly contraindicated; now a labeled instruction for Foundayo — never co-prescribe two GLP-1 RAs
Diabetic Retinopathy
Caution with rapid A1c reductions; monitor baseline retinopathy before initiating
Section 7
Dosing and Titration — Full Class Overview
Dosing and titration are foundational to successful GLP-1 RA therapy because they determine whether patients can stay on treatment long enough to realize meaningful clinical benefit. This is not simply a pharmacokinetic formality or a routine prescribing detail — it is a patient-centered strategy that gives the gastrointestinal tract time to adapt to the drug's mechanism of action. In real-world practice, the titration schedule is often the single most important determinant of persistence, tolerability, and ultimately therapeutic success.
Why Titration Exists
GLP-1 RAs are started at a low dose and advanced slowly so the body can adapt before side effects become treatment-limiting.
What Titration Protects
Gradual escalation reduces nausea, vomiting, fullness, and early discontinuation, the most common barriers to adherence.
What Matters Most
The patient does not need to reach the maximum dose to benefit; the goal is the lowest effective, tolerable dose.
Foundational Concepts — Why Titration Exists
The physiologic reason titration matters is straightforward: GLP-1 receptor agonists slow gastric emptying and act on central appetite-regulating pathways in the hypothalamus and brainstem. These effects are dose-dependent, and when the drug is introduced too quickly, the result is often nausea, vomiting, early satiety, bloating, and general gastrointestinal discomfort.
The gut is not passive in this process, it has neuroadaptive plasticity. With gradual dose escalation over roughly 4 to 8 weeks, vagal and enteric nervous system pathways become less sensitive to the drug's effects, which is why patients who tolerate one dose for several weeks often handle the next step much better. This escalation schedule is not arbitrary; it is grounded in Phase 3 clinical trial protocols specifically designed to balance efficacy with tolerability.

Physiologic basis: slower gastric emptying + central appetite suppression = predictable GI effects when dose increases too quickly.

Adaptive basis: the GI tract develops measurable tolerance over time, which is why stepwise escalation works.
Detailed Explanation — The Titration Table
Use the table below as a quick clinical reference for starting doses, stepwise increases, and typical maintenance targets across the class. In practice, the table is most useful when read from left to right: confirm the correct initiation dose, verify the planned titration interval, and then determine whether the patient's clinical goal has been reached before advancing. The lowest effective dose is usually preferred whenever symptom control, A1c improvement, weight loss, or tolerability goals are being met.
In general, the minimum interval at each titration step is 4 weeks, with one important exception: Foundayo uses 30 days per titration step. There is no maximum time a patient must remain at a given dose, if a sub-maximal dose is working well, it can be continued indefinitely.
The listed maintenance dose is the target, not a requirement. Patients may experience meaningful clinical benefit across the dose range, and the lowest effective dose is preferred whenever possible. Tirzepatide is especially flexible because its maintenance range includes 5, 10, or 15 mg weekly. Liraglutide (Saxenda) has the most stepwise increases, so patients should be counseled from the start that this is a minimum 5-week ramp-up before the full dose is reached.
Mechanism, Why Skipping Steps Causes Discontinuation
When titration is rushed, the neuroadaptive process is overwhelmed before the gut and central nervous system can adjust. That mismatch drives the intense nausea and vomiting that commonly leads to premature discontinuation. Among patients who stop GLP-1 therapy, GI intolerance is the leading reason, and many discontinuations occur early, often within the first 3 months, when titration is still underway.
From a pharmacy perspective, this makes each refill an opportunity to protect adherence: verify that the dose matches the intended escalation plan, especially for the first 2 to 3 fills, and flag any prescription that appears to skip a step or accelerate too quickly.

Clinical risk of rushing: rapid escalation increases the likelihood of dose-limiting nausea, vomiting, dehydration, and complete therapy abandonment.
Restarting After a Lapse — The Restart Rule
The restart rule is one of the most important counseling points in the entire class. After missing 2 or more consecutive weekly doses — or more than 2 weeks for daily agents — the patient's GI adaptation is often lost. Restarting at the previously tolerated dose is a common error and can trigger severe nausea and vomiting, even if the patient had been stable at the highest dose before the interruption.

Correct approach: restart at the lowest starting dose and re-titrate as if the patient were new to therapy.

Weekly-agent exception: a single missed dose may be taken on the next scheduled day if within 5 days of the missed dose. If more than 5 days have passed, skip it and resume the next scheduled dose.
Pharmacists should proactively teach this rule at every fill: “If you miss more than two doses in a row, call us before restarting.” This simple message prevents a highly predictable source of avoidable adverse effects and helps patients re-enter therapy safely after interruptions.
Practical Significance — The Pharmacist's Titration Checklist
First Fill
This is your most important touchpoint. Before the patient walks out the door, do three things: verify the starting dose matches the labeled initiation dose exactly — a prescription written for 2.5 mg tirzepatide on day one is a red flag worth a quick call; hand the patient a written titration schedule so they know what to expect at every step; and set honest expectations about weeks 1 through 4. Tell them: 'Some nausea is normal and expected — it usually peaks in the first two weeks and fades as your body adjusts. That's the drug working, not a sign something is wrong.' That one sentence prevents a lot of unnecessary discontinuations.
Second Fill
Ask before you fill. A simple 'How has your stomach been handling it?' opens the door. If the patient reports significant nausea, vomiting, or that they've barely been eating, do not advance the dose — hold at the current step and document it. Escalating over active GI intolerance is one of the most common pharmacist-preventable errors in this class. If symptoms are mild and improving, reassure them that this is the expected trajectory and confirm they're ready to move to the next step. Document your assessment either way.
Third Fill and Beyond
Every refill from here is a clinical check-in, not just a transaction. First, verify the dose on the new prescription matches the next expected titration step — if it jumps more than one level, flag it before dispensing. Then ask about missed doses the right way: 'Have there been any weeks where you weren't able to take your injection?' is far more likely to get an honest answer than 'Did you miss any doses?' If they missed two or more consecutive weekly doses, the restart rule applies — back to the starting dose, full re-titration, no exceptions. Also check for persistent GI symptoms: if nausea or vomiting is still active, hold the dose rather than escalate. And if the patient has already hit their clinical goal — A1c on target, meaningful weight loss, symptoms improved — there is no requirement to keep climbing. The lowest effective dose is always the right dose.
After Any Gap
When a patient returns after a break in therapy — whether from a shortage, a hospitalization, travel, or simply forgetting — your first question is: how long was the gap? If it was more than two weeks for a weekly agent, or more than two weeks for a daily agent, the GI adaptation built up during titration is gone. Restarting at the previously tolerated dose is a predictable setup for severe nausea and vomiting. The correct move: restart from the lowest starting dose and re-titrate as if they are brand new to the medication. This is not a punishment — it is the safest, most tolerable path back to therapeutic benefit. Make sure the patient understands this before they leave the counter.
Important Nuances
  • Sub-therapeutic dosing is not failure — many patients achieve meaningful A1c reduction and weight loss below the labeled maximum.
  • Dose reduction for tolerability is preferable to discontinuation whenever possible.
  • Patients with gastroparesis or severe GI motility disorders may not tolerate any dose and should be discussed with the prescriber.
  • Oral agents have unique administration requirements; Rybelsus and Foundayo should be counseled differently.
  • Pregnancy planning matters: semaglutide should be discontinued at least 2 months before a planned pregnancy, and other GLP-1 RAs should be stopped per agent-specific guidance.
  • When in doubt, use the lowest effective dose and coordinate any escalation concerns with the prescriber.

CLINICAL PEARL: Rybelsus requires empty stomach, ≤4 oz water, 30-minute post-dose fast. Foundayo has NO such requirement — any time, any food, any water volume. This distinction is the #1 oral GLP-1 counseling point.
Key takeaway: Titration is not a formality — it is the clinical strategy that determines whether a patient stays on therapy long enough to benefit. The pharmacist who reinforces slow titration, manages expectations about early GI effects, and counsels on the restart rule is directly preventing the most common cause of GLP-1 RA failure.
Section 8
Monitoring Parameters
Comprehensive monitoring throughout GLP-1 RA therapy is not optional and it is not merely routine follow-up. It is the clinical infrastructure that makes treatment safe, effective, and sustainable over time. These agents influence multiple organ systems at once — including the pancreas, kidneys, cardiovascular system, gastrointestinal tract, thyroid, gallbladder, and retina — so monitoring must be broader than what is required for most single-indication drug classes.
For the pharmacist, monitoring is not confined to the dispensing counter. It includes proactive symptom screening at every refill, recognition of red-flag findings that require urgent referral, and coordination with prescribers when laboratory values or clinical changes suggest the need for dose adjustment, closer follow-up, or discontinuation. In practice, monitoring is how GLP-1 RA therapy stays aligned with the patient rather than the prescription label.

Why this matters: GLP-1 RAs can improve glycemia, weight, kidney outcomes, and cardiovascular risk, but those benefits are only realized when therapy is actively watched for efficacy and safety.

Clinical principle: A patient who feels “fine” may still be developing silent renal, retinal, or gallbladder complications. Monitoring must anticipate problems before they become emergencies.
Foundational Concepts
Before discussing specific labs and symptoms, it helps to define the framework behind GLP-1 RA monitoring. First, baseline monitoring and ongoing monitoring serve different purposes. Baseline labs and clinical assessment establish the starting point, identify contraindications or pre-existing risk factors, and give the care team something to compare against later. Ongoing monitoring then tracks response, detects emerging adverse effects, and informs whether titration should continue, pause, or stop.
Second, many commonly monitored values are surrogate endpoints rather than clinical outcomes. A1c and eGFR are not the outcome themselves; they are markers that predict downstream outcomes such as cardiovascular events, kidney failure, and long-term microvascular harm. Monitoring them allows clinicians to intervene early, before irreversible damage occurs. That is why these numbers are so valuable even when the patient is not yet reporting symptoms.
Third, monitoring intervals are not arbitrary. They reflect the natural history of the conditions being treated and the known timeline of adverse effects associated with the drug class. The follow-up schedule should become more frequent during initiation and titration, then stabilize once the patient is at a maintenance dose and clinically stable.
Finally, the pharmacist’s role depends on the practice setting. In community pharmacy, monitoring is usually symptom-based and refill-based: asking the right questions, noticing warning signs, and escalating concerns. In ambulatory care or collaborative practice settings, pharmacists may also order, interpret, and trend laboratory values directly.
Glycemic & Renal Parameters
  • Hemoglobin A1c every 3 months until target, then every 6 months
  • eGFR and UACR at baseline, then at least annually; more frequently in CKD
  • Hypoglycemia monitoring when used with insulin or sulfonylureas
Weight & Metabolic Parameters
  • Body weight and BMI at each encounter; document weight trajectory
  • Blood pressure and heart rate at each visit (modest BP reduction; small HR increase common)
  • Lipid panel periodically — non-HDL and triglyceride improvements expected
GI Tolerability & Organ Safety
  • Nausea, vomiting, diarrhea, constipation, early satiety at each visit
  • Signs and symptoms of pancreatitis (severe persistent abdominal pain)
  • Gallbladder disease (RUQ pain, jaundice, fever)
  • For Foundayo: hair loss and liver enzymes given FDA postmarketing requirements
Specialist Monitoring
  • Thyroid symptoms (neck mass, hoarseness, dysphagia, persistent dyspnea)
  • Diabetic retinopathy screening per ADA, especially with rapid A1c declines
  • Injection site assessment for SC formulations
Detailed Explanation — The Four Monitoring Domains
Glycemic & Renal Parameters — Why Each Matters
A1c every 3 months until target: A1c reflects average blood glucose over roughly 3 months, which corresponds to the lifespan of red blood cells. Monitoring every 3 months during titration gives the clinician enough time to see whether the medication is working, whether dose escalation is needed, and whether glycemic improvement is too rapid in a patient also using insulin or a sulfonylurea. Once the patient is stable and at goal, every 6 months is usually sufficient.
eGFR and UACR: eGFR estimates kidney filtration capacity, while UACR detects early kidney injury by measuring albumin leakage into the urine. Together, they provide a practical view of renal health. This matters especially because GLP-1 RAs have demonstrated nephroprotective effects in outcomes trials, including FLOW with semaglutide, making baseline and ongoing renal monitoring important both to document benefit and to detect any unexpected decline. In patients with chronic kidney disease, more frequent monitoring every 3 to 6 months is reasonable.
Hypoglycemia risk: GLP-1 RAs alone have very low intrinsic hypoglycemia risk because their insulin-stimulating effect is glucose-dependent — they work primarily when glucose is elevated. That changes when they are combined with insulin or sulfonylureas, where additive glucose lowering can cause hypoglycemia. Patients on combination therapy should be taught how to recognize and treat low blood sugar, and insulin or sulfonylurea doses may need to be reduced when a GLP-1 RA is added.

Practical tip: If the patient is not diabetic and is using a GLP-1 RA for obesity alone, A1c monitoring is not automatically required. The plan should match the indication and comorbidities.
Weight & Metabolic Parameters — Why Each Matters
Body weight and BMI: Weight trajectory is a primary efficacy endpoint in obesity treatment and an important secondary endpoint in type 2 diabetes. Recording weight at every encounter creates a longitudinal trend that helps show response, supports prior authorization renewals, and identifies non-responders early — often defined as less than 5% weight loss at 12 to 16 weeks. Patients benefit from seeing the data too; someone who has lost 8% of body weight in 4 months should be able to recognize that success clearly.
Blood pressure and heart rate: GLP-1 RAs usually produce modest reductions in systolic blood pressure, typically in the range of about 2 to 5 mmHg, likely through weight loss and natriuresis. They can also cause a small increase in resting heart rate, often about 2 to 4 bpm. That rise is usually clinically insignificant, but it matters in patients with pre-existing tachyarrhythmias or symptomatic palpitations. Measuring both at each visit creates a more complete cardiovascular picture.
Lipid panel: These agents can improve the lipid profile modestly, especially triglycerides and non-HDL cholesterol, with small LDL reductions in some patients. These improvements are secondary to better glycemic control and weight loss rather than a direct lipid-lowering mechanism. Periodic monitoring — generally annually or based on cardiovascular risk — is appropriate.

Clinical value: Weight, blood pressure, and lipid trends often help patients stay engaged because they make the benefits of therapy visible, not just theoretical.
GI Tolerability & Organ Safety — Why Each Matters
GI symptom monitoring: Nausea, vomiting, diarrhea, constipation, and early satiety are the most common adverse effects in the class and a leading reason for discontinuation. Asking about these symptoms at every refill is not a courtesy question — it is an intervention. It gives the pharmacist a chance to recommend dose holds, dietary adjustments, hydration strategies, or antiemetic support before the patient decides on their own that the medication is intolerable.
Pancreatitis: GLP-1 RAs carry a labeled warning for acute pancreatitis. The mechanism is not fully established, and the causal signal remains debated in the literature, but the warning is clinically important. The classic red-flag presentation is severe, persistent mid-epigastric or upper abdominal pain that may radiate to the back. This requires immediate discontinuation of the drug and urgent medical evaluation. Patients should be told explicitly to stop the medication and seek care right away if this occurs.
Gallbladder disease: Rapid weight loss of any cause raises the risk of gallstones and cholecystitis, and GLP-1 RAs can contribute through both weight loss and possible direct effects on gallbladder motility. Right upper quadrant pain, jaundice, fever, and nausea after fatty meals are important warning signs. Patients with a history of gallstones should be monitored especially carefully.
Foundayo-specific monitoring: Orforglipron (Foundayo) has FDA postmarketing requirements for hair loss and liver enzyme monitoring. Alopecia can occur with rapid weight loss across the class, but it was specifically flagged in Foundayo trials. Liver enzyme elevations were seen in a small subset of patients, so periodic ALT and AST monitoring is appropriate per prescribing information. Pharmacists should ask about hair loss and unusual fatigue, which can be a clue to hepatic injury.

Red flag: Persistent severe abdominal pain, jaundice, or vomiting with dehydration should be treated as urgent until proven otherwise.
Specialist Monitoring — Why Each Matters
Thyroid symptoms: Most GLP-1 RAs, except exenatide IR, carry a boxed warning for thyroid C-cell tumors based on rodent data. The human risk is considered low and unproven, but counseling remains important. Patients should report neck mass, hoarseness, difficulty swallowing, or persistent shortness of breath because those symptoms may reflect thyroid pathology that warrants prompt evaluation. This is not a reason to avoid the drug in most patients, but it is a reason to monitor carefully.
Diabetic retinopathy: Rapid A1c reduction — especially a drop of more than 2% within the first 3 to 6 months — has been associated with transient worsening of diabetic retinopathy, a phenomenon known as early worsening. This is well documented with insulin intensification and has also been observed with semaglutide in SUSTAIN-6. Patients with pre-existing moderate to severe retinopathy should have ophthalmology follow-up before and during rapid improvement. This does not mean GLP-1 RAs should be avoided in those patients; the long-term benefit usually outweighs the short-term risk, but monitoring is essential.
Injection site assessment: For subcutaneous formulations, inspect injection sites for lipohypertrophy, which can appear as fatty lumps from repeated injections in the same area. Lipohypertrophy can impair absorption and reduce efficacy. Patients should be taught to rotate sites systematically among the abdomen, thigh, and upper arm and to avoid injecting into areas of visible or palpable lipohypertrophy.

Pharmacy pearl: A patient with stable symptoms still needs ongoing screening. Silent complications are a major reason that “feeling okay” cannot replace structured monitoring.
Practical Significance — The Pharmacist's Monitoring Workflow
Monitoring works best when it is built into routine refill interactions rather than treated as a separate task. At every refill, pharmacists should use a simple structured script and adapt it to the patient's indication, comorbidities, and therapy intensity. The goal is to identify problems early enough to preserve adherence and prevent avoidable harm.
At every refill, ask four key questions: 1) How is your stomach tolerating it? 2) Have you noticed any unusual symptoms — neck swelling, severe abdominal pain, or right-sided pain after eating? 3) Are you checking your blood sugar regularly if you are also on insulin or a sulfonylurea? 4) Have you had any recent labs?
Flag and act: If a patient reports severe abdominal pain, hold the medication and refer urgently. If a patient reports neck swelling or hoarseness, contact the prescriber promptly. If a patient on insulin reports frequent hypoglycemia, the prescriber may need to reduce the insulin dose. If recent labs show a renal decline, unexplained liver enzyme elevation, or rapid A1c drop with retinopathy risk, escalate the concern rather than waiting for the next refill.
Document: Every monitoring conversation should be documented in the dispensing system or patient record. Documentation protects the pharmacist, supports continuity of care, and creates a longitudinal record that helps the entire care team see what was asked, what was found, and what action was taken.

Urgent referral triggers: severe persistent abdominal pain, signs of dehydration, jaundice, neck swelling, progressive dysphagia, or new visual symptoms after rapid glycemic improvement.

Good monitoring changes outcomes: it prevents unnecessary discontinuation, identifies dose-related adverse effects early, and keeps the patient engaged long enough to achieve benefit.
Important Nuances
  • Not all monitoring applies to all patients: a patient using a GLP-1 RA for obesity without diabetes does not need A1c monitoring, and a patient without CKD does not need quarterly eGFR.
  • Tailor the monitoring plan to the indication and comorbidities, rather than applying every lab to every patient automatically.
  • Monitoring frequency should increase during titration and stabilize once the patient reaches a maintenance dose.
  • The absence of symptoms does not mean the absence of risk: pancreatitis and gallbladder disease can develop silently before becoming acute.
  • Proactive counseling about warning signs is more valuable than waiting for the patient to report them spontaneously.
  • When in doubt, coordinate with the prescriber early rather than after the patient has already stopped therapy.

Remember: the monitoring plan should evolve over time. Early therapy is about tolerability and dose response; later therapy is about maintaining benefit and catching complications that may appear after the patient feels well.
Key takeaway: Monitoring GLP-1 RA therapy is not a checkbox — it is an ongoing clinical conversation. The pharmacist who asks the right questions at every refill, recognizes the red flags, and acts on abnormal findings is the last line of defense between a preventable adverse event and a patient who simply stops coming back.
Section 9
Adverse Effects and Risk Mitigation
Common Adverse Effects
  • Nausea — most common; dose-dependent; improves over 4–8 weeks
  • Vomiting, diarrhea, constipation
  • Decreased appetite (desired, but monitor nutritional intake)
  • Dyspepsia, abdominal pain, eructation
  • Injection site reactions (SC formulations)
  • Fatigue, headache
  • Hair loss — notable with Foundayo; seen across the class with rapid weight loss; counsel proactively
  • Gastroesophageal reflux disease — listed in Foundayo labeling
Serious Adverse Effects
  • Pancreatitis — discontinue immediately if suspected
  • Acute kidney injury — typically from GI-related volume depletion
  • Cholelithiasis / cholecystitis — increased risk in trials and meta-analyses
  • Hypoglycemia — significant risk when combined with insulin or sulfonylureas
  • Diabetic retinopathy progression with rapid A1c reductions
  • Thyroid C-cell tumors — see boxed warning
  • Pulmonary aspiration during anesthesia — explicitly listed in Foundayo labeling
Risk Mitigation Strategies
  • Adhere strictly to recommended titration schedules — do not accelerate
  • Counsel on maintaining hydration (≥64 oz/day) to reduce AKI risk
  • Recommend smaller, more frequent meals; avoid high-fat foods early in therapy
  • Reduce or discontinue insulin/sulfonylureas when initiating GLP-1 RA in well-controlled patients
  • Discontinue immediately for severe persistent abdominal pain, persistent severe vomiting, or signs of intestinal obstruction
  • Counsel all patients on hair loss — it is real, reported, and addressable
Section 10
Drug Interactions
Drug interactions with GLP-1 receptor agonists matter clinically because they are easy to miss. Unlike the classic interaction patterns most clinicians are trained to watch for — especially hepatic enzyme induction or inhibition through CYP450 pathways — GLP-1 RA interactions are driven primarily by a single physiologic mechanism: delayed gastric emptying. That makes the profile both predictable and underappreciated. It is predictable because the mechanism is consistent across the class; it is underappreciated because a changing drug level is often attributed to the other medication, diet, adherence, or disease state, not to the GLP-1 RA. This is exactly where the pharmacist adds unique value: at the point of dispensing, the pharmacist is often the last person who can catch a clinically meaningful interaction before the patient is harmed.
In practice, the interaction pattern is less about “drug-drug conflict” in the traditional sense and more about how a GLP-1 RA changes the timing and sometimes the extent of absorption of oral medications. That is why the most important questions are not “Does this drug use CYP3A4?” but “Is this drug narrow therapeutic index?”, “Is this drug dependent on precise timing?”, and “Does this patient also take insulin, a sulfonylurea, or oral contraceptives?”

Clinical takeaway: GLP-1 RA interaction screening should be systematic, not reflexive. The highest-risk combinations are usually found by manually reviewing the full medication list, not by relying on automated alerts alone.
Foundational Concepts
Delayed Gastric Emptying
GLP-1 RAs slow the rate at which the stomach empties its contents into the small intestine. This is an intentional pharmacologic effect that contributes to satiety, smaller meal size, and improved postprandial glucose control. The same mechanism, however, also means that orally administered medications remain in the stomach longer before reaching the small intestine, where most absorption occurs. Clinically, this can delay the time to peak concentration (T_{max}), reduce peak concentration (C_{max}), and in some cases reduce total exposure (AUC). The significance depends on the drug, its therapeutic window, and the degree of gastric emptying delay.
Narrow Therapeutic Index Drugs
Narrow therapeutic index (NTI) drugs are medications in which small changes in blood concentration can cause serious harm. If levels rise too high, toxicity occurs; if they fall too low, therapy fails. Common examples include warfarin, levothyroxine, phenytoin, digoxin, and lithium. With these agents, even modest absorption changes can move a patient from therapeutic to subtherapeutic or toxic.
Pharmacokinetic vs. Pharmacodynamic Interactions
Most GLP-1 RA interactions are pharmacokinetic — they affect how much drug gets into the body or how quickly it gets there. The major exception is the additive glucose-lowering effect seen with insulin and sulfonylureas, which is a pharmacodynamic interaction because the drugs’ effects on glucose lowering add together.
The Foundayo Nuance
Orforglipron (Foundayo) is a non-peptide oral GLP-1 RA that does not require the SNAC absorption enhancer used by Rybelsus. Even so, it still activates GLP-1 receptors in the gut and slows gastric emptying. That means it carries the same absorption-based interaction risks as injectable GLP-1 RAs, despite being an oral formulation. This is a common misconception and worth addressing explicitly.

Oral does not mean interaction-free. The route of the GLP-1 RA itself does not remove the gastric-emptying effect that drives many clinically relevant interactions.
Insulin & Secretagogues
Concurrent use with insulin, sulfonylureas, or meglitinides substantially increases hypoglycemia risk. Consider dose reduction of the insulin or secretagogue at GLP-1 RA initiation. Do not wait for symptomatic hypoglycemia before adjusting — act proactively at the time of prescribing.
Narrow Therapeutic Index Drugs
Delayed gastric emptying may alter the absorption of warfarin, levothyroxine, certain antiepileptics, and other narrow-therapeutic-index medications. Monitor INR, TSH, and clinical response after GLP-1 RA initiation or dose changes. This applies to all GLP-1 RAs, including Foundayo.
DPP-4 Inhibitors
Concurrent use of a GLP-1 RA with a DPP-4 inhibitor is not recommended — overlapping mechanisms with no demonstrated additive benefit. One should be discontinued before the other is initiated.
Oral Contraceptives (Tirzepatide)
Tirzepatide may reduce the efficacy of oral hormonal contraceptives, particularly during dose escalation. Counsel patients to use a non-oral or barrier method for 4 weeks after initiation and after each dose increase.
Dual GLP-1 RA Use
Co-administration of two GLP-1 receptor agonists is explicitly contraindicated. Now a labeled warning for Foundayo — do not co-prescribe with any other GLP-1 RA, injectable or oral, even at microdosed levels.
Detailed Explanation — The Five Interaction Categories
Insulin & Secretagogues — The Hypoglycemia Risk in Detail
GLP-1 RAs lower blood glucose through glucose-dependent insulin stimulation and glucagon suppression. That glucose-dependent mechanism is one reason they are generally safer than older therapies. But when a GLP-1 RA is combined with insulin — which lowers glucose regardless of the current glucose level — or with sulfonylureas or meglitinides — which stimulate insulin release independently of glucose — the effects can stack and push the patient into hypoglycemia. In other words, the GLP-1 RA does not usually cause dangerous lows by itself, but it can make an already potent regimen too strong.
This is why proactive dose reduction matters. Waiting until the patient reports symptomatic hypoglycemia is reactive and exposes them to an event that could have been prevented. A standard approach is to reduce the insulin or sulfonylurea dose by approximately 10–20% when the GLP-1 RA is started, then adjust based on home glucose monitoring, clinical response, and A1c trend. The goal is not simply to “watch and wait”; it is to anticipate the interaction and prevent it.
Patients at highest risk include those on high-dose insulin, those with tighter baseline glycemic control (for example, A1c near 6.5–7%), older adults, and anyone with impaired hypoglycemia awareness. These patients may not recognize early warning symptoms, which increases the chance that a mild low becomes a severe one.

Counseling message: Tell patients that their blood sugar medication may need to be adjusted now that they are starting a GLP-1 RA. Review the symptoms of hypoglycemia — shakiness, sweating, confusion, rapid heartbeat — and teach them to treat mild lows with 15 grams of fast-acting carbohydrate.
Narrow Therapeutic Index Drugs — A Systematic Approach
For most medications, a modest change in absorption timing is clinically unimportant. For NTI drugs, however, even a relatively small shift in T_{max} or C_{max} can matter. Delayed gastric emptying means the medication spends longer in the stomach before reaching the small intestine, where absorption typically occurs. That change may be subtle, but in an NTI drug it can be enough to alter the clinical effect.
Warfarin is a practical example. Delayed absorption can contribute to INR fluctuations, but the response is inherently unpredictable because warfarin effect also depends on vitamin K intake, interacting medications, adherence, and genetics. The practical approach is to monitor INR more frequently after GLP-1 RA initiation or any dose change and to counsel patients on bleeding and clotting symptoms.
Levothyroxine is another high-sensitivity drug. Its absorption is affected by timing, food, and co-administered medications even under ideal circumstances. A GLP-1 RA may further slow or alter absorption, so TSH should be checked 6–8 weeks after GLP-1 RA initiation and after each dose change. Patients should continue taking levothyroxine on an empty stomach exactly as directed.
Antiepileptics such as phenytoin, carbamazepine, and valproate can also be vulnerable because they have narrow therapeutic windows and may be monitored by serum levels. Altered absorption timing can affect peak levels and seizure control. If a patient on an antiepileptic is starting a GLP-1 RA, coordinate with the prescriber and consider whether monitoring or dose adjustment is needed.
Oral antibiotics and other time-sensitive medications deserve attention as well, especially when timing of peak concentration matters or when the medication has food-dependent absorption characteristics. Even if the interaction is not severe, counseling can prevent confusion if a patient notices a change in effect.

General rule: For any NTI drug, flag the interaction at dispensing, notify the prescriber, and establish a monitoring plan before the patient starts the GLP-1 RA.
DPP-4 Inhibitors — Why the Combination Fails
DPP-4 inhibitors — sitagliptin, saxagliptin, alogliptin, and linagliptin — work by blocking the enzyme that degrades endogenous GLP-1. That increases native incretin activity, but only modestly. They are oral, generally well tolerated, and produce a milder glucose-lowering effect than GLP-1 RAs.
The problem is mechanism overlap. GLP-1 RAs directly activate GLP-1 receptors at supraphysiologic levels. Once those receptors are already being strongly stimulated by an exogenous agonist, adding a DPP-4 inhibitor does not meaningfully increase receptor activation. The DPP-4 inhibitor’s mechanism is essentially redundant.
Clinical trials have not shown meaningful additive A1c reduction with the combination, yet the patient still inherits extra pill burden, extra cost, and the potential for added adverse effects. From a practical standpoint, the combination creates complexity without benefit.
When transitioning a patient from a DPP-4 inhibitor to a GLP-1 RA, the DPP-4 inhibitor should be stopped first. Pharmacists should treat a prescription containing both as a therapeutic duplication alert and verify whether one agent is intended to be discontinued.
Oral Contraceptives — The Tirzepatide-Specific Warning
Tirzepatide deserves special attention because its dual GLP-1/GIP mechanism produces a more pronounced gastric emptying delay than single GLP-1 RAs, particularly during dose escalation when the effect is strongest. That can reduce the absorption of oral hormonal contraceptives and lower plasma concentrations below the threshold needed for reliable ovulation suppression.
The clinical concern is unintended pregnancy. This is not theoretical — it is a labeled warning in tirzepatide prescribing information.
Recommended management is straightforward: patients should use a non-oral contraceptive method — such as a patch, ring, IUD, implant, injection, or barrier method — or add a barrier method for at least 4 weeks after initiating tirzepatide and for 4 weeks after each dose increase. Once the dose is stable, the interaction risk diminishes as gastric emptying stabilizes, but counseling should occur before the prescription is filled, not after the patient notices a problem.

This warning is currently specific to tirzepatide, not all GLP-1 RAs, but the mechanism is plausible across the class. Counsel proactively when oral hormonal contraception is being used.
Dual GLP-1 RA Use — An Absolute Contraindication
This issue matters now because the approval of Foundayo (orforglipron) as an oral GLP-1 RA creates a real-world risk of therapeutic duplication. A patient already taking semaglutide or tirzepatide could be prescribed Foundayo — or vice versa — and the oral-versus-injectable distinction may obscure the fact that both agents are GLP-1 receptor agonists.
The risks are not trivial: additive gastrointestinal toxicity, including severe nausea, vomiting, and dehydration; excessive glucose lowering; and unknown pharmacodynamic consequences from dual receptor saturation. There is no clinical scenario in which dual GLP-1 RA therapy is appropriate.
The pharmacist is uniquely positioned to catch this at the drug utilization review stage. Dispensing systems may not always flag an oral GLP-1 RA against an injectable one if the medications are categorized differently, so manual verification of the full medication list is essential before any GLP-1 RA is dispensed.

This is now a labeled contraindication in the Foundayo prescribing information. Screening for dual GLP-1 RA use is both a professional and legal obligation.
Practical Significance — The Pharmacist's Drug Interaction Workflow
Every new GLP-1 RA prescription should trigger a structured review. Start with the automated interaction screen, but do not stop there. Manually check the medication list for the five high-value categories that matter most in practice: insulin or sulfonylureas, narrow therapeutic index drugs, DPP-4 inhibitors, oral contraceptives if tirzepatide is involved, and any other GLP-1 RA.
  • Insulin or sulfonylureas: discuss proactive dose reduction rather than waiting for hypoglycemia.
  • NTI drugs: flag the interaction and notify the prescriber before dispensing.
  • DPP-4 inhibitors: identify therapeutic duplication and clarify the intended regimen.
  • Oral contraceptives with tirzepatide: provide contraceptive counseling and backup method guidance.
  • Any other GLP-1 RA: treat as an absolute contraindication and intervene immediately.
At dose escalation, repeat the NTI-drug review and the oral contraceptive review. The gastric-emptying effect is often more pronounced during titration, so the interaction risk can intensify when the dose changes. Documentation matters as well: record every interaction counseling conversation and any prescriber communication so the intervention is traceable.
Important Nuances
The gastric-emptying effect is dose-dependent and most pronounced during titration. Once the patient reaches a stable maintenance dose, the interaction risk tends to stabilize, but it does not disappear completely.
Injectable and oral GLP-1 RAs carry the same absorption-based interaction risks. The route of administration of the GLP-1 RA itself does not change its physiologic effect on gastric emptying.
Not all oral medications are equally affected. Drugs with wide therapeutic windows — such as most statins and most antihypertensives — are unlikely to cause clinical problems from modest absorption changes. The main focus should be NTI drugs and medications where timing of peak concentration matters.
The oral contraceptive warning is currently labeled only for tirzepatide, but the mechanism is plausible for other GLP-1 RAs. If a patient uses oral hormonal contraception, counsel proactively and document the conversation even when the label does not specifically require it.
GLP-1 RA drug interactions are mechanistically predictable but clinically underappreciated. The pharmacist who reviews the full medication list at every new prescription and dose change — not just the automated DUR screen — is the most reliable safeguard against the interactions that matter most: hypoglycemia from insulin combinations, toxicity from narrow-therapeutic-index drugs, contraceptive failure from tirzepatide, and the silent danger of dual GLP-1 RA prescribing.
Section 11
Patient Counseling Points
Effective patient counseling is the most consistent predictor of adherence and long-term persistence with GLP-1 RA therapy. Community and ambulatory care pharmacists are uniquely positioned to deliver the comprehensive medication education that drives real-world outcomes — particularly as this class expands to cover complex multi-system indications and multiple oral and injectable formulations simultaneously on the market. Counseling should be individualized by route, indication, and patient-specific adherence barriers.
For Injectable Agents
Inject subcutaneously into the abdomen, thigh, or upper arm; rotate sites to prevent lipohypertrophy. Choose a consistent day of the week for weekly agents; set a phone reminder. Use a new needle for each injection. Never share pens. Dispose of needles in an FDA-approved sharps container. Unopened pens belong in the refrigerator; once opened, follow agent-specific storage guidance.
For Foundayo (Oral)
Take once daily at the same time for routine — but timing relative to meals does not matter. With or without food, any time of day, any volume of water. This is NOT the same as Rybelsus. Store at room temperature like any other oral solid dosage form. Report hair loss and nausea proactively.
Universal GI Guidance
Nausea is the most common side effect, is typically mild-to-moderate, and usually improves over 4–8 weeks. Eat smaller, more frequent meals. Avoid high-fat or greasy foods early in therapy. Stop eating when full. Maintain hydration — at least 64 oz of fluid daily unless contraindicated.
When to Call the Prescriber
Report severe persistent abdominal pain (pancreatitis), persistent severe vomiting, signs of gallbladder disease (RUQ pain, jaundice, fever), new neck mass or hoarseness, or any change in mood or behavior. For patients with diabetes, review symptoms of hypoglycemia if also on insulin or a sulfonylurea.
Indication-Specific Counseling Scripts
The following evidence-based counseling scripts are field-tested for community pharmacy application. Adapt language to the patient's health literacy level while preserving the core clinical messages.
OSA (Tirzepatide)
"This is not a breathing medicine like your CPAP. It is a weight-loss medicine that reduces fatty tissue around your airway. CPAP works faster, but tirzepatide changes the underlying disease over time."
Kidney Disease
"This medicine protects your kidneys by reducing inflammation. It works differently from your SGLT2 inhibitor, and the two together provide more protection than either alone."
Cardiovascular Risk
"Research shows this medicine reduces the risk of heart attack and stroke, even beyond what the weight loss alone would do. That's why your prescriber chose it."
Shortage / Switching
"Some GLP-1 is better than none. We're restarting at a lower dose and going slow to avoid nausea. Do not assume dose-for-dose match — treat this like a fresh titration."
Foundayo vs Injectable
"Foundayo works, but it's not quite as strong as Wegovy or Zepbound. Expect about 10%–12% weight loss, not the 15%–20% with injectables. Trade-off: no needles, no cold storage, no fasting."
Section 12
Special Populations
Pediatrics
Liraglutide (Victoza ≥10 yr; Saxenda ≥12 yr), dulaglutide (≥10 yr for T2DM), and semaglutide (Wegovy ≥12 yr) have age-specific approvals. Weight-based dosing is not used. Foundayo is NOT approved in children — safety and efficacy not established. Do not use orforglipron off-label in pediatric patients at this time.
Renal Impairment
Most agents do not require dose adjustment in mild-to-moderate impairment. Exenatide is not recommended at eGFR <30 mL/min/1.73 m². Semaglutide and tirzepatide may be used across the eGFR spectrum with close monitoring. Foundayo carries an AKI warning (volume depletion) but does not have eGFR-based dose adjustments in current labeling.
Hepatic Impairment
Limited data in severe hepatic impairment — use all agents with caution. FDA postmarketing requirements for Foundayo specifically include hepatic safety studies; pharmacist vigilance regarding hepatic adverse events is warranted until these data mature.
Pregnancy & Lactation
Contraindicated in pregnancy and lactation. Discontinue at least 2 months before planned pregnancy for weekly agents to allow drug clearance (~5 half-lives). For Foundayo (~29–49 hr half-life), a shorter washout is pharmacokinetically sufficient, but pre-conception discontinuation is still recommended given limited human reproductive safety data.
Geriatric Patients
No specific dose adjustments required, but monitor closely for volume depletion (AKI risk), sarcopenia, and nutritional status with significant weight loss. GI side effects may be more pronounced; titrate conservatively in older adults with frailty or polypharmacy.
Bariatric Surgery Candidates
An emerging role exists both pre-operatively (to achieve threshold BMI or reduce metabolic risk) and post-operatively. Coordinate all GLP-1 RA decisions with the bariatric surgical team; GI side effects may be additive with post-surgical dumping syndrome.
Section 13 — Real-World Practice
The Pharmacist's Domain
Beyond evidence and guidelines, pharmacists are the front line for the operational challenges that determine whether GLP-1 therapy actually works for a given patient. This section addresses the "how patients get hurt in real life" scenarios — drug shortages, missed doses, self-pay access, switching dilemmas, microdosing risks, compounded products, and the practical integration of Foundayo into a rapidly evolving formulary landscape. These are not academic exercises; they are the daily realities of GLP-1 dispensing in 2026.

PHARMACIST MANTRA: "Some GLP-1 is better than none." A reduced or alternative agent at the right dose maintains far more clinical benefit than a therapy gap. This principle applies to shortages, formulary changes, and patient-driven dose modifications alike.
Drug Shortages — Practical Moves That Work
What Actually Works
  • Step down dose temporarily (e.g., tirzepatide 15 mg → 10 mg) to extend supply — clinical benefit is maintained at lower doses
  • Coordinate with the prescriber for a temporary alternative agent within the class
  • Verify pharmacy distribution status weekly during active shortages; FDA shortage database and wholesaler portals are the most current sources
  • Document all shortage-related communications with prescribers and patients — this protects the patient, the prescriber, and the pharmacy
  • Foundayo's 2026 launch may reduce shortage pressure on injectable obesity products as needle-averse and pill-preference patients transition to the oral non-peptide option
Avoid
  • Combining two pens to reach a higher dose — no evidence base; insurance will not cover it
  • Allowing patients to take unplanned therapy gaps without a documented bridge plan
  • Assuming dose-for-dose equivalence when crossing products during a shortage switch
Missed Dose Rules
Weekly injectable agents:
  • If >48 hours remain before next scheduled dose → administer missed dose immediately
  • If <48 hours remain → skip and resume next scheduled day
  • Multiple weeks missed → restart titration from a lower dose
Foundayo (daily oral):
  • If remembered same day → take as soon as remembered
  • If already the next day → skip the missed dose and resume regular schedule
  • Do NOT double up
  • After several missed days → consider stepping back one dose level at restart
Switching Between GLP-1 RAs — A Clinical Framework
Patients switch GLP-1 RAs for multiple real-world reasons: shortages, insurance formulary changes, cost, poor efficacy, GI intolerance, or the emergence of a new comorbidity (ASCVD, CKD, OSA) that favors a different agent. Switching evidence is limited — most guidance is practical and individualized rather than trial-proven. Key studies include SURPASS SWITCH-2 (switching to tirzepatide produced greater A1c and weight reductions) and SURPASS-SWITCH (tirzepatide outperformed escalated dulaglutide). No published switching trials exist for Foundayo.
Questions to Ask Before Every Switch
01
Current Therapy Status
What is the current GLP-1 RA and dose? When was the last dose? Have any doses been missed recently?
02
Treatment History
How long has the patient been on this agent? What side effects have they experienced? Is the switch due to intolerance, formulary, or efficacy?
03
Therapeutic Goal
What is the primary driver — A1c, weight, CV risk, kidney protection, or OSA? The goal should drive the agent selection, not just formulary availability.
04
Access and Coverage
What does the patient's insurance cover? Is a prior authorization required for the new agent? Has the PA been submitted before dispensing?

PATIENT PITFALL: "I was on tirzepatide 5 mg, so I should start Foundayo at 5.5 mg" — or — "I was on tirzepatide 5 mg, so I should start Wegovy at 2.4 mg." Both are incorrect and frequently lead to severe GI intolerance and discontinuation. Always restart at the lowest dose and re-titrate. For Foundayo, ALWAYS start at 0.8 mg regardless of prior therapy — there is no published mg-equivalence to injectable peptides.
Alternative Dosing — Microdosing and Interval Extension
Microdosing — What It Is and Why It Happens
Microdosing refers to using lower-than-labeled doses, typically achieved by counting dial clicks on a multidose pen. Patients pursue this strategy to reduce GI side effects, stretch supply during shortages, lower costs, or transition between agents. It is off-label, not well-studied, and explicitly opposed by package labeling.
Ozempic 1 mg pen math: 1 mg ≈ 72 clicks; each click ≈ 0.0139 mg. A patient counting 54 clicks delivers approximately 0.75 mg (54 ÷ 72 = 0.75 mg).

Foundayo cannot be microdosed by clicks — it is an oral tablet at six fixed strengths, and tablet splitting is not manufacturer-supported.
Safer-Use Strategies for Microdosing
  • Only consider with multidose pens — never with single-dose pens or single-use vials
  • Confirm patient vision, dexterity, hearing, cognition, and literacy
  • Provide written instructions; perform teach-back
  • Use a new needle for every injection
  • Track first-use date; discard Ozempic pen after 56 days
Half-Life Reference — Interval Extension Context

Microdosing risks: dose miscalculation, inconsistent dosing, refill timing problems, pen expiration, reduced or unknown CV/kidney benefit at sub-labeled doses, contamination risk, and patient confusion. Document in the patient's medication profile.
Compounded GLP-1 Products — Safety and Legal Framework
Federal law generally prohibits compounding a product that is essentially a copy of an FDA-approved medication. The principal exception applies when the FDA-approved product is on shortage; once the shortage resolves, copy-compounding must stop after a defined transition period. As the GLP-1 market normalizes and Foundayo enters the oral non-peptide space, pharmacists should expect an influx of online marketing for compounded "oral GLP-1" products positioned alongside or as alternatives to Foundayo.

WARNING: Compounded GLP-1 RAs are NOT FDA-approved and are not generic, biosimilar, or bioequivalent to FDA-approved products. High-risk example: patients have administered 5–20× the intended semaglutide dose due to syringe-measurement confusion, resulting in severe adverse events. Anticipate online compounded "orforglipron" or "oral GLP-1 pill" products — these are NOT Foundayo and carry all compounded-product risks.
Major Safety Concerns with Compounded GLP-1 Products
  • Variable drug concentrations
  • Dosing errors — especially syringe-based measurement
  • Contamination
  • Wrong ingredient or wrong salt form
  • Lack of safety and efficacy data
  • Misleading online marketing
  • Additives (B6/B12) without supporting evidence
  • Alternative dosage forms (sublingual) without supporting evidence
Counterfeit / Suspect-Product Red Flags
  • Dose missing from the package label
  • Labels with smudges or difficult-to-read print
  • "Use 1 pen weekly" without specifying the dose in mg
  • No physician or pharmacy name on the label
  • Unusual product appearance or unclear instructions

Always add compounded GLP-1 products to the patient's medication profile for screening of duplications, contraindications, interactions, and perioperative concerns.
Beyond-Use Date vs Expiration Date — Compounding Reference
CSP Storage Limits by Category

503A vs 503B: 503A facilities are state-licensed compounding pharmacies producing patient-specific compounds — they are NOT FDA-registered for large-batch production. 503B outsourcing facilities are FDA-registered and may produce larger batches under cGMP-like standards. This distinction matters for compounded GLP-1 product sourcing and quality assurance.
Section 14
Perioperative Management of GLP-1 RAs
GLP-1 receptor agonists cause nausea, vomiting, delayed gastric emptying, and reduced oral intake — each of which carries direct implications for the perioperative period. Potential concerns include aspiration risk during anesthesia, post-operative nausea and vomiting, delayed gastric emptying contributing to diagnostic confusion with ileus or surgical complications, and hyperglycemia if the agent is held in a patient with insulin-requiring diabetes. A thoughtful, patient-specific, team-based approach is essential.

CLINICAL PEARL: Recommendations vary across professional societies. Use shared decision-making with the anesthesia and procedure teams, document the rationale, and confirm whether patient-specific factors — recent dose escalation, ongoing GI symptoms, high aspiration risk — justify a longer hold period.
Perioperative — Continue vs Hold Decision Framework
Consider CONTINUING if:
  • Patient is stable on the current dose for ≥4 weeks
  • No significant ongoing GI symptoms
  • Not currently in the dose-escalation phase
  • Low aspiration risk (procedure type and patient factors)
  • Procedure team in agreement with continuation
Consider HOLDING if:
  • Severe nausea or vomiting on the current dose
  • Unable to reliably tolerate oral intake pre-procedure
  • Recent therapy initiation or recent dose escalation
  • High dose with significant residual GI symptoms
  • Known gastroparesis or other elevated aspiration risk factors
Hold Recommendations by Agent Class
Perioperative — Fasting, Clear Liquids, and Restart
Standard Fasting Guidelines (If Continuing)
  • Solids: nothing by mouth for up to 8 hours before anesthesia
  • Clear liquids: may continue up to 2 hours before (standard ASA guidance)
  • Some experts prefer no/low-calorie clear liquids stopped 2–4 hours before; high-carb clear liquids stopped ~8 hours before
  • Some centers recommend a 24-hour clear liquid diet before anesthesia for patients on GLP-1 RAs — discuss with the proceduralist
Acceptable Clear Liquids
  • Water; tea or coffee without milk/creamer
  • Apple juice or cranberry juice (no pulp)
  • Gatorade or Powerade; soda or seltzer
  • Clear fat-free broth; plain gelatin; popsicles (no fruit or milk)
  • For colonoscopy: avoid restricted colors if instructed (commonly red and purple)
Diabetes Perioperative Targets
  • A1c goal often <8% if achievable prior to elective surgery
  • Blood glucose target near surgery: 100–180 mg/dL within 4 hours of the procedure
  • Surgery should be postponed only for severe hyperglycemic emergencies (DKA or HHS)
Restarting After Surgery
  • Restart when patient has returned to a usual diet
  • No severe nausea or vomiting present
  • No significant post-operative GI dysfunction
  • If multiple doses were missed → restart at a lower dose and re-titrate to mitigate GI side effects
Clinical Vignettes
Section 15
Case Scenarios
The following clinical vignettes illustrate real-world application of the principles covered in this continuing education activity. Each case is designed to reinforce agent selection, regimen optimization, switching strategy, perioperative management, and the appropriate use of Foundayo. Work through each case before reading the answer rationale.
1
Phil — Part 1: Initial Encounter
Scenario: BMI 36.9; T2DM, hypertension, hyperlipidemia; failed prior weight-loss medications.
Best Choice: Tirzepatide.
Why: Maximum A1c lowering, maximum weight loss, plus future-facing benefit across CV, renal, and OSA domains.
Optimization: Consider stopping glyburide to mitigate hypoglycemia risk.
2
Phil — Part 2: Updated
Scenario: Now with T2DM, obesity; eGFR ~50 mL/min/1.73 m²; likely elevated cardiovascular risk.
Best Choice: Semaglutide or tirzepatide.
Why: A1c lowering, weight loss, cardiovascular benefit, and renal protection.
Optimization: Stop or reduce glyburide to avoid hypoglycemia.
3
Phil — Part 3: Final Answer
Scenario: T2DM, BMI ~37, eGFR ~50, multiple CV risk factors.
Best Choice: Injectable semaglutide (Ozempic).
Why: FDA-approved for CV benefit, CKD benefit (2025), strong A1c and weight reduction.
Optimization: Stop glyburide; consider adding SGLT2 inhibitor if not already on one.
1
Ari — Switching Scenario
Scenario: Currently on tirzepatide 5 mg weekly; last dose 2 days ago; insurance now prefers Wegovy.
Best Choice: No single "best" — use shared decision-making. Conservative: Wegovy 0.25 mg weekly. Middle-ground: Wegovy 1 mg weekly.
AVOID: Direct jump to Wegovy 2.4 mg — GI intolerance risk is high.
2
Sofia — Perioperative Scenario
Scenario: Tirzepatide 15 mg weekly; stable >6 months; occasional nausea only when overeating; colonoscopy scheduled.
Best Choice: Continue tirzepatide and follow standard fasting recommendations.
Rationale: Long-term stability; no severe GI symptoms; nausea is situational. Document shared decision-making with the proceduralist.
3
Mara — Foundayo Initiation
Scenario: 47F, BMI 32, hypertension, no T2DM; strong needle aversion; no MTC/MEN-2; asks about "the new GLP-1 pill."
Best Choice: Foundayo 0.8 mg PO once daily.
Counseling: Any time of day, any food/water; nausea expected but improves; hair loss possible; expect ~10%–12% weight loss. Titrate: 0.8 → 2.5 → 5.5 mg with ≥30 days each step.
4
Todd — Foundayo Limitations
Scenario: 58M, T2DM (A1c 8.9%), BMI 34, established ASCVD with prior MI, eGFR 48, UACR 220 mg/g. Prescriber writes for Foundayo because "patient prefers a pill."
Best Choice: Decline as written; call the prescriber.
Why: Foundayo is NOT approved for T2DM, CV risk, or CKD. Recommend Ozempic + SGLT2 inhibitor instead.
Section 16
Clinical Decision Framework — Agent Selection by Patient Profile
Section 16.2
High-Yield Clinical Pearls
Tirzepatide — Most Potent, No MACE Indication
Most potent agent across A1c, weight loss, and OSA. Lacks a formal MACE indication in contrast to semaglutide, liraglutide, and dulaglutide — a critical prescribing distinction for patients with established ASCVD.
Subcutaneous Semaglutide — The Workhorse
Best balance of efficacy and accessibility. FDA approvals span T2DM, weight management, CV risk reduction (including in obesity without T2DM via SELECT), and CKD. The single most versatile agent in the class.
Injectable ≠ Oral for Kidneys
Injectable semaglutide carries the FDA CKD indication (FLOW). Oral semaglutide (SOUL) showed no significant kidney benefit. This is a meaningful clinical distinction — Foundayo does not change this hierarchy.
OSA — A Paradigm Shift
For the first time in modern medicine, a metabolic drug (tirzepatide) is approved to treat a respiratory condition. This represents a fundamental conceptual shift in how clinicians and patients should understand GLP-1 RAs.
Foundayo — What It Is and Isn't
First oral non-peptide GLP-1 RA; approved exclusively for chronic weight management. Expected ~10%–12% weight reduction at 17.2 mg. NOT a T2DM agent. NOT approved for CV/CKD/HF/OSA. Take any time of day, any food/water — unlike Rybelsus.
The Pharmacist's Role Is Enormous
Selection, switching, access, safety, compounded-product counseling, perioperative planning, shortage management — all fall within the pharmacist's domain. No other provider is better positioned to translate GLP-1 evidence into safe, individualized patient outcomes.
Final Course Bottom Line
GLP-1 receptor agonists are no longer "diabetes shots." They are central to the management of T2DM, obesity, ASCVD risk reduction, CKD protection, OSA, HFpEF symptom improvement, and PAD functional benefit. With the April 2026 FDA approval of Foundayo (orforglipron), the class now includes its first oral non-peptide small-molecule member — expanding access without redrawing the efficacy hierarchy. GLP-1 therapy is no longer about "which drug lowers A1c?" It is about which drug fits the patient's entire systemic disease profile. This is the GLP-1 era.
Section 17
Self-Assessment Questions
The following six multiple-choice questions assess mastery of the core learning objectives. Read each question and all distractors carefully before selecting your answer. Answers and detailed rationale appear in the following section. Each rationale references the corresponding citation from Section 18.
1
Question 1 — Microdosing Math
A patient asks why Reed's pharmacist measured 0.75 mg from an Ozempic 1 mg pen using 54 dial clicks. Based on the standard click-to-dose conversion for the Ozempic 1 mg pen, which best describes the relationship?
A. 1 mg ≈ 54 clicks; each click ≈ 0.0185 mg
B. 1 mg ≈ 72 clicks; each click ≈ 0.0139 mg
C. 1 mg ≈ 100 clicks; each click ≈ 0.01 mg
D. Click-counting is not applicable to the Ozempic 1 mg pen
2
Question 2 — MACE Indication
Which of the following carries an FDA-approved indication for reduction of major adverse cardiovascular events (MACE)?
A. Exenatide ER (Bydureon BCise)
B. Dulaglutide (Trulicity)
C. Oral semaglutide (Rybelsus)
D. Tirzepatide (Mounjaro)
3
Question 3 — Half-Life Application
Liraglutide has a half-life of approximately 13 hours. After how many days is the drug expected to be mostly eliminated, applying the standard "~5 half-lives" rule?
A. 1 day
B. 2.5 days
C. 5 days
D. 7 days
4
Question 4 — Agent Selection
A patient with T2DM, BMI 37, eGFR ~50, hypertension, and hyperlipidemia is on metformin and glyburide. What is the most appropriate add-on GLP-1 RA?
A. Exenatide IR; continue glyburide unchanged
B. Subcutaneous semaglutide (Ozempic); reduce or stop glyburide
C. Liraglutide (Victoza); add a sulfonylurea for tighter control
D. Oral semaglutide (Rybelsus); continue glyburide unchanged
5
Question 5 — Compounding Law
Which of the following statements about compounded GLP-1 RAs is TRUE?
A. Compounded GLP-1 RAs are FDA-approved generic equivalents
B. 503A pharmacies are FDA-registered for large-batch production under cGMP
C. Federal law generally prohibits compounding copies of FDA-approved drugs, with a limited shortage exception
D. Patients need not inform their care team when starting a compounded GLP-1 RA
6
Question 6 — Foundayo Counseling
A 45-year-old patient with BMI 31 and hypertension asks about Foundayo. Which statement is MOST accurate?
A. "Foundayo is the same as Rybelsus — empty stomach, small sip of water, wait 30 minutes."
B. "Foundayo is approved for both weight loss and type 2 diabetes."
C. "Foundayo is once daily, any time, any food/water. Expect ~10%–12% weight reduction at the highest dose."
D. "Foundayo has the same indications as tirzepatide, including OSA."
Answer Key and Rationale
1
Q1 — Correct Answer: B
The Ozempic 1 mg multidose pen delivers 1 mg over approximately 72 dial clicks (~0.0139 mg per click). Therefore, 54 clicks ≈ 0.75 mg. This microdosing strategy is off-label, opposed by manufacturer labeling, and carries documented risks of dose miscalculation and inconsistent delivery. Foundayo cannot be microdosed by clicks — it is a fixed-strength oral tablet.
2
Q2 — Correct Answer: B
Dulaglutide (Trulicity) is FDA-approved for cardiovascular risk reduction in T2DM patients with established CVD or multiple CV risk factors (REWIND). Liraglutide (LEADER) and subcutaneous semaglutide (SUSTAIN-6/SELECT) carry similar indications. Exenatide failed to demonstrate superiority in EXSCEL. Oral semaglutide and tirzepatide do not currently carry formal MACE indications.
3
Q3 — Correct Answer: B
After ~5 half-lives, a drug is mostly eliminated. For liraglutide (t½ ≈ 13 hr): 13 × 5 = 65 hr ≈ 2.7 days; the best discrete answer is 2.5 days. This contrasts with weekly agents (semaglutide ~35 days to full elimination; tirzepatide ~25–30 days) and illustrates why perioperative hold durations differ substantially by agent.
4
Q4 — Correct Answer: B
Subcutaneous semaglutide (Ozempic) is the only GLP-1 RA with FDA approvals for both CV risk reduction and CKD risk reduction in T2DM (based on FLOW, 2025). Glyburide must be reduced or stopped — the combination with a GLP-1 RA substantially increases hypoglycemia risk without CV or renal benefit. Oral semaglutide did not demonstrate kidney benefit in SOUL. Foundayo is not labeled for T2DM.
5
Q5 — Correct Answer: C
Federal law generally prohibits compounding copies of FDA-approved medications; the principal exception applies during a recognized shortage. 503A pharmacies are state-licensed for patient-specific compounding — not FDA-registered for large-batch production (that is 503B). Compounded GLP-1 RAs are not FDA-approved, not generics, not biosimilars. Patients should always notify their care team when using compounded products so the medication profile is accurate.
6
Q6 — Correct Answer: C
Foundayo (orforglipron) is approved for chronic weight management in adults with BMI ≥30 or BMI ≥27 + comorbidity. Unlike Rybelsus (SNAC-dependent, strict empty-stomach requirement), Foundayo has no food, timing, or water-volume restrictions. It is NOT approved for T2DM, ASCVD, CKD, HFpEF, or OSA. ATTAIN-1 data show ~11%–12.4% weight reduction at 17.2 mg — meaningful but less than the 15%–20% with tirzepatide. Option C is the only fully accurate counseling statement.
Section 18
References
The following references support the evidence base presented in this continuing education activity. All citations are listed in the order in which they appear in the course content.
Core Guidelines
1. American Diabetes Association. Standards of Care in Diabetes — 2025. Diabetes Care. 2025;48(Suppl 1).
2. Pratley RE, et al. The expanding indications and clinical role of GLP-1 receptor agonists. Lancet Diabetes Endocrinol. 2024;12(8):506–520.
6. KDIGO Diabetes Work Group. KDIGO 2024 Clinical Practice Guideline for CKD in Diabetes. Kidney Int. 2024;105(4S):S117–S314.
17. ADA. 9. Pharmacologic approaches to glycemic treatment — 2025. Diabetes Care. 2025;48(Suppl 1):S181–S206.
Mechanism and Pharmacology
3. Drucker DJ. Mechanisms of action and therapeutic application of GLP-1. Cell Metab. 2018;27(4):740–756.
4. Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab. 2018;20(Suppl 1):5–21.
5. Coskun T, et al. LY3298176 (tirzepatide). Mol Metab. 2018;18:3–14.
Cardiovascular Outcome Trials
22. Lincoff AM, et al. SELECT trial — semaglutide and CV outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221–2232.
23. Holman RR, et al. EXSCEL — exenatide weekly and CV outcomes in T2DM. N Engl J Med. 2017;377(13):1228–1239.
Renal and Heart Failure Trials
24. Perkovic V, et al. FLOW trial — semaglutide on CKD in T2DM. N Engl J Med. 2024;391(2):109–121.
25. Kosiborod MN, et al. STEP-HFpEF — semaglutide in HFpEF and obesity. N Engl J Med. 2023;389(12):1069–1084.
26. Packer M, et al. SUMMIT — tirzepatide in HFpEF. N Engl J Med. 2025;392(5):427–437.
OSA, PAD, Weight Management Trials
8. Malhotra A, et al. SURMOUNT-OSA — tirzepatide for OSA. N Engl J Med. 2024;391(13):1193–1205.
27. Bonaca MP, et al. STRIDE trial — semaglutide in T2DM and PAD. Lancet. 2025;405(10477):842–852.
18. Wilding JPH, et al. STEP 1 — semaglutide weekly in overweight/obesity. N Engl J Med. 2021;384(11):989–1002.
19. Jastreboff AM, et al. SURMOUNT-1 — tirzepatide for obesity. N Engl J Med. 2022;387(3):205–216.
Foundayo (Orforglipron) References
33. FDA. FDA Approves First NME Under National Priority Voucher Program. April 1, 2026. fda.gov
34. Eli Lilly. FDA approves Foundayo (orforglipron) press release. April 1, 2026.
35. Eli Lilly.